TrialJournal of Crohn's & colitis2023
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
Fenna M Jansen et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.